These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18794908)

  • 41. The Affymetrix DMET platform and pharmacogenetics in drug development.
    Deeken J
    Curr Opin Mol Ther; 2009 Jun; 11(3):260-8. PubMed ID: 19479659
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenomics of antidepressant drugs.
    Horstmann S; Binder EB
    Pharmacol Ther; 2009 Oct; 124(1):57-73. PubMed ID: 19563827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacogenetic-assisted drug development. Regulatory aspects from the viewpoint of the Medical Products Agency].
    Theilade MD
    Ugeskr Laeger; 2005 May; 167(20):2146-50. PubMed ID: 15987069
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug discovery and development in the age of molecular medicine.
    Vallance P; Levick M
    Clin Pharmacol Ther; 2007 Oct; 82(4):363-6. PubMed ID: 17851574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of plasmid-derived external quality control samples in pharmacogenetic testing.
    van der Straaten T; Swen J; Baak-Pablo R; Guchelaar HJ
    Pharmacogenomics; 2008 Sep; 9(9):1261-6. PubMed ID: 18781854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenetic testing in psychiatry: a review of features and clinical realities.
    de Leon J; Arranz MJ; Ruaño G
    Clin Lab Med; 2008 Dec; 28(4):599-617. PubMed ID: 19059065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenetic testing: time for clinical practice guidelines.
    Amstutz U; Carleton BC
    Clin Pharmacol Ther; 2011 Jun; 89(6):924-7. PubMed ID: 21508939
    [No Abstract]   [Full Text] [Related]  

  • 50. Nurses' genetic/genomics competencies when medication therapy is guided by pharmacogenetic testing: children with mental health disorders as an exemplar.
    Prows CA; Saldaña SN
    J Pediatr Nurs; 2009 Jun; 24(3):179-88. PubMed ID: 19467430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics: practices and opportunities for study design and data analysis.
    Flynn AA
    Drug Discov Today; 2011 Oct; 16(19-20):862-6. PubMed ID: 21875683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenetic testing in schizophrenia and posttraumatic stress disorder.
    Ramey-Hartung B; El-Mallakh RS; Reynolds KK
    Clin Lab Med; 2008 Dec; 28(4):627-43. PubMed ID: 19059067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacogenetics in breast cancer therapy.
    Tan SH; Lee SC; Goh BC; Wong J
    Clin Cancer Res; 2008 Dec; 14(24):8027-41. PubMed ID: 19088019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Undertaking positive control studies as part of developmental neurotoxicity testing: a report from the ILSI Research Foundation/Risk Science Institute expert working group on neurodevelopmental endpoints.
    Crofton KM; Foss JA; Hass U; Jensen KF; Levin ED; Parker SP
    Neurotoxicol Teratol; 2008; 30(4):266-87. PubMed ID: 17681747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bridging the knowledge gaps in vaccine design.
    Rappuoli R
    Nat Biotechnol; 2007 Dec; 25(12):1361-6. PubMed ID: 18066025
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacogenetics in heart failure: promises and challenges.
    de Boer RA; van der Harst P; van Veldhuisen DJ; van den Berg MP
    Expert Opin Pharmacother; 2009 Aug; 10(11):1713-25. PubMed ID: 19558337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of pharmacogenetics in anticoagulation therapy.
    Hill CE; Duncan A
    Clin Lab Med; 2008 Dec; 28(4):513-24. PubMed ID: 19059059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Present-day problems of clinical pharmacogenetics].
    Kukes VG; Sychev DA; Gasanov NA
    Klin Med (Mosk); 2007; 85(2):58-63. PubMed ID: 17520892
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.